Abstract:Immunological treatment is a new therapeutic approach for treatment of Alzheimer's Diseases(AD) . Now a cell line of expressing fusion antibody in yeast system was established, this antibody is composed by two parts. One part(A) is designed to recongnize Aβ and conjugate it (the sequence has been patent) . The others comes from human Fc. The fusion antibody acts as natural antibodies against amyloid β-peptide triggered microglialcell to clear plaques through Fc receptor-mediated phagocytosis. The pAO815-αAFc expression vector can be under the control of tightly regulated alcohol oxidase(AOX1) promoter and the gene encoding the fusion antibody was fused in fame to the S.cerevisiae α-mating factor leader sequence,that is, the secretion of fusion antibody depends on the secretion signal sequence of α-factor. The vector can be linearized by enzyme and transformed into Pp. Therefore the expression strains would show good genetic stability during growth even under non-selective conditions. To increase the yield of fusion antibody and minimize the proteolytic process of fusion antibody secreted in the culture medium, the conditions of expressing and culturing were optimized .The yield of fusion antibody in superatant of 1L flake pine culture is at the level of 100mg/L. Through Protein A affinity chromatography, the fusion antibody with high purity and biological activity was obtained. It owns correct MW, N-terminal amino acid sequence and shows the biological activity of combining Aβ and stimulating microphage to clear Ag+Ab complex. It may provide a new potential approach to treat and study Alzheimer's disease.

High Level Expression Purification and Character Research of Human Fusion Antibody for Anti-Aβ in the Yeast Pichia Pastoris